| In vitro studies have demonstrated that nafamostat mesylate has antiviral activity and appears to be one of the most potent drugs against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). |
| Clinical trials to date are limited but suggest a potential benefit of nafamostat in patients with severe coronavirus disease 2019 (COVID-19). |
| Current evidence from case reports and observational studies provides guidance for potential adverse effects. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.